ストックスクリーナーアプリを入手
8.42
6.13%
-0.55
アフターアワーズ：
8.36
-0.06
-0.71%
前日終値:
$8.97
開ける：
$8.97
24時間の取引高:
4.10M
Relative Volume:
0.91
時価総額：
$1.37B
収益：
$1.08B
当期純損益:
$422.82M
株価収益率:
3.693
EPS:
2.28
ネットキャッシュフロー:
$-637.33M
1週間 パフォーマンス:
+6.99%
1か月 パフォーマンス:
+8.65%
6か月 パフォーマンス:
-0.71%
1年 パフォーマンス:
+7.54%
1日の値動き範囲:
$8.25
$9.19
1週間の範囲:
$7.845
$9.276
52週間の値動き範囲:
$5.01
$10.64
Novavax Inc Stock (NVAX) Company Profile
Compare NVAX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.42 | 1.46B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-20 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 開始されました | Citigroup | Sell |
| 2025-02-28 | 開始されました | BTIG Research | Buy |
| 2024-07-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-05-10 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-10 | アップグレード | JP Morgan | Underweight → Neutral |
| 2023-08-09 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 繰り返されました | B. Riley Securities | Buy |
| 2022-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-12-02 | 開始されました | Jefferies | Hold |
| 2022-09-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2022-02-22 | 再開されました | Jefferies | Buy |
| 2022-01-21 | 開始されました | Cowen | Outperform |
| 2021-05-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-05 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-08-05 | ダウングレード | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 繰り返されました | B. Riley FBR | Buy |
| 2020-06-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 繰り返されました | B. Riley FBR | Buy |
| 2020-05-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-08-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-28 | ダウングレード | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-12-11 | 開始されました | Oppenheimer | Outperform |
| 2018-11-26 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | アップグレード | JP Morgan | Underweight → Overweight |
| 2018-03-29 | アップグレード | Seaport Global Securities | Neutral → Buy |
すべてを表示
Novavax Inc (NVAX) 最新ニュース
Why institutional investors increase stakes in Novavax Inc. (NVV1) stockWeekly Market Outlook & Entry and Exit Point Strategies - mfd.ru
The Truth About Novavax Inc (NVAX): Comeback Story or Total Bag Fumble? - AD HOC NEWS
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
Human Vaccine Adjuvants Market Forecast with Size and Share Analysis 2026 to 2035 - Insightace Analytic
Novavax, Inc. (NVAX) Investor Outlook: Exploring a Potential 48.15% Upside in the Biotechnology Arena - DirectorsTalk Interviews
Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX - MarketBeat
(NVAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RSI Check: Is Novavax Inc a defensive stockMarket Rally & Reliable Price Breakout Signals - baoquankhu1.vn
Market Review: Is Novavax Inc a defensive stockProduct Launch & Verified Momentum Stock Watchlist - baoquankhu1.vn
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax rises after a seven-day slide - MSN
Novavax, Inc. (NVAX) Stock Analysis: Assessing a 48% Potential Upside Amidst Market Challenges - DirectorsTalk Interviews
Why Novavax (NVAX) Dipped More Than Broader Market Today - Yahoo Finance
Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story - Yahoo Finance
Pfizer Reshapes Portfolio With Metsera Deal Novavax Pact And R&D Push - simplywall.st
Pfizer Q4 Earnings Preview: Analysts Expect Decline - Intellectia AI
Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Earnings Update: Can Novavax Inc stock outperform in a bear marketJuly 2025 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Novavax COVID-19 vaccine approved by the FDA - MSN
Weekly Earnings: Is Novavax Inc a turnaround storyGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
AI Stocks: Whats the beta of Novavax Inc stockPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets - Finviz
Assessing Novavax’s (NVAX) Valuation After Its New Matrix M Licensing Agreement With Pfizer - Sahm
Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
9 High Growth Small Cap Stocks That Are Profitable - Insider Monkey
Moderna Vs. Novavax: 2 Pandemic Vaccine PioneersWhich Offers Better Value Today? (MRNA) - Seeking Alpha
Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx - Yahoo Finance
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - Finviz
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? - The Motley Fool
Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline - Finviz
Here's Why Novavax (NVAX) Fell More Than Broader Market - Yahoo Finance
Why Is Pfizer Stock Rising Tuesday? - Sahm
Has Novavax cracked the code for survival in the vaccine arena? - PharmaVoice
Novavax, Inc. (NASDAQ:NVAX) Given Average Rating of "Hold" by Analysts - MarketBeat
Pfizer Reshapes Pipeline With Novavax Deal And ViiV Exit - simplywall.st
Responsive Playbooks and the NVAX Inflection - Stock Traders Daily
Novavax rises after licensing deal with Pfizer - MSN
Novavax, Inc. (NVAX) Stock Analysis: Exploring a 33.84% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
What's Driving the Market Sentiment Around Novavax Inc? - Benzinga
MRNA vs NVAX: Which vaccine stock is Wall Street more bullish on right now? - MSN
Novavax (NASDAQ:NVAX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant - Sahm
Decliners Report: Is Novavax Inc a play on infrastructure spendingRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Will Licensing Novavax’s Matrix-M Adjuvant Reshape Pfizer’s (PFE) Vaccine Platform Strategy? - Yahoo Finance
Reassessing Novavax (NVAX) After Recent Share Price Rebound And Valuation Signals - Yahoo Finance
Novavax grants license for use of Matrix-M adjuvant to Pfizer - MSN
Novavax (NVAX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Novavax Pfizer Licensing Deal Puts Matrix M And Valuation In Focus - Sahm
Key facts: Novavax signs $30M deal with Pfizer; shares rise 19.7% - TradingView — Track All Markets
Novavax, Inc.'s (NASDAQ:NVAX) Price Is Right But Growth Is Lacking After Shares Rocket 46% - 富途牛牛
Novavax Inc (NVAX) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):